Esophageal cancer incidence is growing worldwide, especially adenocarcinomas in the western world. Outcomes overall are universally poor, with the best survival seen in earlier stages of the disease, where surgery is the mainstay of treatment.
| INTRODUC TI ON
The global incidence of esophageal cancer is on the rise, ranking seventh in terms of incidence and sixth in overall mortality worldwide. 1 Predominant histological types are adenocarcinoma and squamous cell carcinoma (SCC), which differ in their epidemiology, tumor biology and pathogenesis. Treatment strategies for different histological subtypes should be separate; however, both are traditionally treated primarily with surgical resection. 2 Low cure rates and poor survival associated with esophageal cancer has brought about a shift in the management strategy from locoregional therapy alone to multimodality regimens. Nevertheless, surgery remains the mainstay of most regimens with addition of chemotherapy or chemoradiotherapy in the treatment of locally advanced disease. 3 Preoperative therapy (neoadjuvant) appears to offer theoretical advantages over postoperative therapy (adjuvant) to control the micrometastases early. Intact blood supply to the tumor may improve the delivery and effectiveness of chemotherapy and radiotherapy. There is a potential to downstage the tumor and facilitate curative (R0) resection. It may also help to identify tumors with aggressive biological behavior and therefore guide further treatment. However, associated disadvantages of preoperative therapy have to be taken into consideration as it can increase both morbidity and mortality of surgery. There could be technical difficulties of operating in a pretreated field, especially with the addition of radiation, resulting in impaired healing of anastomosis and an increase in postoperative pulmonary complications. Hence, the ideal neoadjuvant treatment should be able to treat micrometastasis, improve survival by preventing local as well as distant failures, and have minimum toxicity and postoperative complications.
Although it is possible that chemotherapy and radiation could act synergistically at a locoregional level, the question remains as to whether there is value in combining two local treatments-radiation and surgery. Hence, the optimal treatment regimen for esophageal cancer is still controversial.
| NEOADJ U VANT CHEMOTHER APY
Over the last three decades, extensive research has been done on neoadjuvant treatment for resectable esophageal cancers.
Chemotherapy in the preoperative as well as adjuvant setting has been studied. Several randomized trials have compared neoadjuvant chemotherapy (NACT) followed by surgery with surgery alone ( Table 1) . Two-drug or three-drug combinations have been used as first-line therapy in esophageal cancer. Most of the earlier trials were not adequately powered to definitively answer the question about the value of preoperative chemotherapy.
Among the appropriately powered, large-scale studies are the US Intergroup trial 113, 4 which randomized 213 esophageal cancer patients to perioperative chemotherapy (cisplatin + 5-fluorouracil) and 227 patients to surgery alone. This trial failed to show a significant difference in overall survival (OS) and R0 resection rates (59% vs 63%) between the two groups. Adverse effects of chemotherapy were tolerable and there was no increase in postoperative morbidity or mortality due to the addition of chemotherapy. Both squamous cell carcinoma and adenocarcinoma patients had similar survival curves.
The next large trial was the Medical Research Council (MRC, UK) randomized trial on neoadjuvant chemotherapy in esophageal cancer (OEO2). 5 It compared 400 patients receiving NACT followed by surgery with 402 patients who underwent surgery alone. Contrary to the Intergroup trial, this study showed a survival benefit with NACT with R0 resection rates (60% vs 54%) and 5-year overall survival (23% vs 17%) favoring the NACT arm.
Postoperative complications were similar in both groups. These treatment results were consistent in adenocarcinoma as well as in SCC patients. The Japanese Clinical Oncology Group (JCOG) conducted a trial JCOG 9907 8 to ascertain the optimal timing of perioperative chemotherapy. A total of 330 esophageal SCC patients were randomized either to postoperative or preoperative chemotherapy with cisplatin and 5-FU. Analyses showed that the 5-year survival was better in the preoperative arm (55% vs 43%) without any additional adverse events.
Comparing different chemotherapy regimens, OEO5 and FLOT4 are recent studies of importance. The UK MRC OEO5 trial 9 compared the conventional cisplatin/5-FU (CF) regimen with four cycles of epirubicin/cisplatin/capecitabine (ECX) in esophageal adenocarcinoma. R0 resection rates and postoperative complications were similar between the two regimens and there was also no significant difference in median survival (18 months CF vs 21 months ECX), thereby questioning the role of epirubicin in esophageal cancer. The German FLOT4 study 10 randomized patients with gastric or GEJ adenocarcinoma to the docetaxel, oxaliplatin, 5-FU with leucovorin (FLOT/ DOF) regimen or to the conventional MAGIC regimen (ECF/ECX). Analyses of 716 patients in this study showed dramatic differences in both PFS as well as 3-year OS (57% vs 48%) favouring the FLOT arm. With these results, the standard of care for esophageal and GEJ adenocarcinomas seems to be moving towards FLOT rather than the conventional ECF regimen. Most recent trials as well as meta-analyses 11, 12 clearly show the superiority of neoadjuvant chemotherapy followed by surgery over surgery alone. Importantly, this benefit is seen without an increase in treatment-related morbidity or mortality.
| NEOADJ U VANT CHEMOR ADIATION
Neoadjuvant chemoradiation (NACRT) has the advantage of combining chemotherapy and radiation prior to surgery, and addressing both locoregional disease as well as micrometastases. Several trials were carried out to evaluate whether neoadjuvant chemoradiation followed by surgery could improve survival over surgery alone ( Table 2 ); most of the earlier studies were small and underpowered to detect a difference. In the Irish trial, 13 The EORTC trial 14 Studies with statistically significant results are in bold. with surgery alone. Here, radiation was delivered in two one-weekly courses, 2 weeks apart, with five daily fractions of 3.7 Gy each; cisplatin was given before each course of radiation. A total of 282 patients were randomized, 139 to surgery alone and 143 to combined treatment. Complete pathological response was seen in 26% of patients with combined treatment. In this trial, recruitment was stopped earlier than anticipated because of higher mortality in the combined treatment group. After a median follow up of 55.2 months, there was no significant difference in overall survival between the two groups.
TA B L E 2 Summary of neoadjuvant chemoradiation (NACRT) trials in esophageal cancer
Esophagus cancer-related deaths were lower in the neoadjuvant group, although mortality due to other causes was higher. The probable cause of the higher mortality rate was attributed to the higher dose of radiation per fraction. 12 Drawbacks of this study included the unconventional fractionation, higher dose of radiation per fraction, a 2-week gap in radiation treatment and the use of cisplatin monotherapy. Our calculated guess is that NACRT is likely to be superior to NACT in squamous cell carcinomas and of no additional benefit to NACT in adenocarcinomas.
| TARG E TED THER APY AND IMMUNOTHER APY
Several years ago, there was a lot of promise and hype about targeted therapy and this has been assessed in a few studies.
Panitumumab was evaluated in a German phase II trial (NEOPECX) 28 and phase III multicentre study (REAL 3), 29 where patients were randomized to receiving conventional MAGIC (ECX/EOX) with or without panitumumab, three cycles pre-and three cycles postoperatively; however, the studies showed no difference in outcomes with the addition of panitumumab. Similarly with bevacizumab, there was a non-randomized phase II study 30 and the addition of bevacizumab to cisplatin/5-FU compared to historical controls showed no difference in outcomes. The MRC phase III trial comparing the addition of bevacizumab to the MAGIC regimen 31 also showed no evidence for the use of bevacizumab with perioperative chemotherapy. Successes with immunotherapy in several cancers have sparked interest and research in evaluating its role in esophageal cancer.
Checkpoint inhibitors are being tested in studies, with observational studies showing remarkable response rates with pembrolizumab 32 and nivolumab 33 -both drugs have shown response rates superior to chemotherapy alone. However, these were observational studies and need to be validated in well-conducted randomized trials. O RCI D C. S. Pramesh https://orcid.org/0000-0002-3635-0083
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